NCT06888063招募中2 期
Preventing Liver Recurrence After Partial Hepatectomy for Intrahepatic Cholangiocarcinoma Using Adjuvant Hepatic Arterial Infusion Pump Chemotherapy - PUMP IV Trial
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Two-year hepatic recurrence free survival (hRFS)
研究概览
简要总结
The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery. The main questions it aims to answer are:
- Does addition of chemotherapy by means of a chemo pump lead to less return of disease within the liver two years after surgery?
- Does addition of chemotherapy by means of a chemo pump lead to longer survival of patients?
- Does addition of chemotherapy by means of a chemo pump lead to an increase in quality of life?
Participants will receive an implanted chemo pump, through which additional chemotherapy will be given to the liver in addition to surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older
- •ECOG or WHO performance status 0 or 1
- •Diagnosis of resectable iCCA on imaging. No histological confirmation is needed before surgery, according to standard of care.
- •Patient is able to undergo a laparotomy.
- •Positioning of a catheter for HAIP chemotherapy is technically feasible based on a CT-scan with early arterial phase with 1mm cuts. The default site for the catheter insertion is the GDA. Accessory or aberrant hepatic arteries are no contraindication for catheter placement.
- •Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old)
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10^ 9/L
- •White blood cell count (WBC) ≥ 2.5 x 10^9/L
- •Platelets ≥ 100 x 10^9/L
- •Glomerular filtration rate (GFR) ≥ 30 ml/min
- •Haemoglobin (Hb) ≥ 5.5 mmol/L
- •Total bilirubin ≤ 25 µmol/L
- •Written informed consent must be given according to ICH/good clinical practice (GCP), and national/local regulations.
排除标准
- •Presence of extrahepatic disease at the time of first presentation. Patients with locoregional lymph node disease or with small (≤ 1 cm) extrahepatic lesions that are too small to characterize or biopsy are eligible.
- •Second primary malignancy, except for adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence or with a life expectancy longer than 5 years.
- •Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency
- •Prior hepatic radiation, ablation, or resection for iCCA.
- •Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Some postoperative ascites is allowed.
- •(Partial) portal vein thrombosis in future liver remnant.
- •Pregnant or lactating women.
- •History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy.
- •Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
- •Organ allografts requiring immunosuppressive therapy.
- •Serious infections (uncontrolled or requiring treatment).
- •Participation in another interventional study for iCCA with survival as outcome.
- •Participation in another prospective study with an interventional medical product.
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
研究组 & 干预措施
Surgery + chemo pump (Hepatic Arterial Infusion Pump chemotherapy)
Experimental
Surgery + chemo pump
干预措施: Hepatic Arterial Infusion Pump chemotherapy with floxuridin (Combination Product)
结局指标
主要结局
Two-year hepatic recurrence free survival (hRFS)
时间窗: From pump implantation until 2 years after that surgery
The percentage of patients who do not have return of disease in the liver two years after surgery. The time frame is defined as the period between pump implantation and return of disease in the liver. A recurrence is defined as a biopsy-proven recurrent lesion or radiological evidence with cross-sectional imaging in combination with an elevated CA19.9 or CEA level in the blood samples.
次要结局
- Overall recurrence free survival (RFS)(From pump implantation until the earliest return of disease in the body during the study (up to 5 years after inclusion))
- Overall survival (OS)(From pump implantation until death or lost to follow-up during the study (up to 5 years after inclusion))
- Post-operative complications(From pump implantation until 90 days after surgery)
- Chemotherapy related adverse events (AEs)(From inclusion until 4 weeks after the end of treatment with chemotherapy)
- Proportion of patients started with HAIP chemotherapy(From pump implantation until the first cycle of HAIP chemotherapy, on average between 4 and 16 weeks after implantation of the HAIP chemopump)
- Quality of life: EORTC QLQ-30(From inclusion until 5 years after surgery)
- Quality of life: EQ-5D(From inclusion until 5 years after surgery)
- Cost-effectiveness(From implantation of the chemo pump until 2 years after (=timeframe of the primary outcome))
- Predictive biomarkers in the blood for efficacy of HAIP chemotherapy(From implantation of the chemo pump until 1 year after surgery or return of disease (whichever comes first))
- Predictive biomarkers from liver tissue for efficacy of HAIP chemotherapy(From resection until 25 years after (conform applicable laws))
研究者
Bas Groot Koerkamp, MD, PhD
Principal Investigator and Professor of Pancreato-Biliary Surgery
Erasmus Medical Center
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy with Systemic TherapyFloxuridineLiver MetastasesVascular Access DeviceColorectal NeoplasmsNCT06857773The Netherlands Cancer Institute306
终止
不适用
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic ReserveChemoembolizationHepatocellular CarcinomaNCT02147301University of California, San Francisco17
进行中（未招募）
1 期
Preventing liver recurrence after partial hepatectomy for intrahepatic cholangiocarcinoma using adjuvant hepatic arterial infusion pump chemotherapy – PUMP IV trialIntrahepatic cholangiocarcinoma (iCCA)CTIS2024-513726-33-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)40
招募中
3 期
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNACirculating Tumor CellCancer, Therapy-RelatedLiver MetastasesColorectal CancerNCT05797077Sixth Affiliated Hospital, Sun Yat-sen University346
已完成
2 期
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)Cholangiolar CarcinomaCholangiocellular CarcinomaPeripheral CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT01862315Memorial Sloan Kettering Cancer Center56